

# Marc Surez-Calvet

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3829043/marc-suarez-calvet-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

122  
papers

4,361  
citations

34  
h-index

65  
g-index

158  
ext. papers

5,998  
ext. citations

6.1  
avg, IF

5.09  
L-index

| #   | Paper  | IF   | Citations |
|-----|--|------|-----------|
| 122 | CSF p-tau231: A biomarker for early preclinical Alzheimer?. <i>EBioMedicine</i> , <b>2022</b> , <i>77</i> , 103936   | 8.8  |           |
| 121 | Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study.. <i>Lancet Neurology, The</i> , <b>2022</b> , <i>21</i> , 329-341                              | 24.1 | 4         |
| 120 | Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility.. <i>Nature Reviews Neurology</i> , <b>2022</b> ,   | 15   | 4         |
| 119 | Leveraging large multi-center cohorts of Alzheimer disease endophenotypes to understand the role of Klotho heterozygosity on disease risk. <i>PLoS ONE</i> , <b>2022</b> , <i>17</i> , e0267298  | 3.7  | 1         |
| 118 | Comparative Analysis of Different Definitions of Amyloid- $\beta$ Positivity to Detect Early Downstream Pathophysiological Alterations in Preclinical Alzheimer. <i>Journal of Prevention of Alzheimer's Disease, The</i> , <b>2021</b> , <i>8</i> , 68-77 | 3.8  | 7         |
| 117 | Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum. <i>JAMA Neurology</i> , <b>2021</b> , <i>78</i> , 1471-1483  | 17.2 | 18        |
| 116 | P-tau235: a novel biomarker for staging preclinical Alzheimer's disease. <i>EMBO Molecular Medicine</i> , <b>2021</b> , <i>13</i> , e15098   | 12   | 4         |
| 115 | Cerebral amyloid- $\beta$ load is associated with neurodegeneration and gliosis: Mediation by p-tau and interactions with risk factors early in the Alzheimer's continuum. <i>Alzheimer's and Dementia</i> , <b>2021</b> , <i>17</i> , 788-800             | 1.2  | 3         |
| 114 | DHA intake relates to better cerebrovascular and neurodegeneration neuroimaging phenotypes in middle-aged adults at increased genetic risk of Alzheimer disease. <i>American Journal of Clinical Nutrition</i> , <b>2021</b> , <i>113</i> , 1627-1635      | 7    | 3         |
| 113 | CSF sTREM2 is elevated in a subset in GRN-related frontotemporal dementia. <i>Neurobiology of Aging</i> , <b>2021</b> , <i>103</i> , 158.e1-158.e5   | 5.6  | 2         |
| 112 | Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. <i>JAMA Neurology</i> , <b>2021</b> , <i>78</i> , 396-406  | 17.2 | 41        |
| 111 | Cognitively unimpaired individuals with a low burden of A $\beta$ pathology have a distinct CSF biomarker profile. <i>Alzheimer's Research and Therapy</i> , <b>2021</b> , <i>13</i> , 134   | 9    | 4         |
| 110 | The BDNF SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer's disease. <i>Molecular Psychiatry</i> , <b>2021</b> , <i>26</i> , 614-628  | 15.1 | 34        |
| 109 | Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum. <i>Brain</i> , <b>2021</b> , <i>144</i> , 325-339   | 11.2 | 42        |
| 108 | Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative. <i>Molecular Psychiatry</i> , <b>2021</b> , <i>26</i> , 429-442   | 15.1 | 70        |
| 107 | Effects of pre-analytical procedures on blood biomarkers for Alzheimer's pathophysiology, glial activation, and neurodegeneration. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2021</b> , <i>13</i> , e12168        | 5.2  | 12        |
| 106 | Association between polygenic risk score of Alzheimer's disease and plasma phosphorylated tau in individuals from the Alzheimer's Disease Neuroimaging Initiative. <i>Alzheimer's Research and Therapy</i> , <b>2021</b> , <i>13</i> , 17                  | 9    | 11        |

|     |  |      |   |
|-----|--|------|---|
| 105 | Association of weight change with cerebrospinal fluid biomarkers and amyloid positron emission tomography in preclinical Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , <b>2021</b> , 13, 46   | 9    | 2 |
| 104 | Amyloid- $\beta$ -positive individuals with subjective cognitive decline present increased CSF neurofilament light levels that relate to lower hippocampal volume. <i>Neurobiology of Aging</i> , <b>2021</b> , 104, 24-31   | 5.6  | 2 |
| 103 | Perivascular spaces are associated with tau pathophysiology and synaptic dysfunction in early Alzheimer's continuum. <i>Alzheimer's Research and Therapy</i> , <b>2021</b> , 13, 135   | 9    | 0 |
| 102 | Enhancing the Sensitivity of Memory Tests: Reference Data for the Free and Cued Selective Reminding Test and the Logical Memory Task from Cognitively Healthy Subjects with Normal Alzheimer's Disease Cerebrospinal Fluid Biomarker Levels. <i>Journal of Alzheimer's Disease</i> , <b>2021</b> , 84, 119-128 | 4.3  | 1 |
| 101 | CSF Synaptic Biomarkers in the Preclinical Stage of Alzheimer Disease and Their Association With MRI and PET: A Cross-sectional Study. <i>Neurology</i> , <b>2021</b> , 97, e2065-e2078  | 6.5  | 2 |
| 100 | Associations between air pollution and biomarkers of Alzheimer's disease in cognitively unimpaired individuals. <i>Environment International</i> , <b>2021</b> , 157, 106864   | 12.9 | 7 |
| 99  | Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview.. <i>Alzheimer's and Dementia</i> , <b>2021</b> ,  | 1.2  | 3 |
| 98  | Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. <i>Alzheimer's and Dementia</i> , <b>2021</b> , 17,   | 1.2  | 1 |
| 97  | Protective genetic variants in the MS4A gene cluster modulate microglial activity. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e039431   | 1.2  | 1 |
| 96  | Impact of the APOE gene on amyloid deposition in participants with abnormal soluble amyloid levels. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e042955  | 1.2  |   |
| 95  | Amyloid- $\beta$ /tau, synaptic dysfunction, neurodegeneration, glial and vascular biomarkers in the preclinical stage of the Alzheimer's continuum. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e044444   | 1.2  |   |
| 94  | Emerging beta-amyloid pathology is associated with tau, synaptic, neurodegeneration and gray matter volume differences. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e044466  | 1.2  | 0 |
| 93  | Genetically predicted telomere length and Alzheimer's disease endophenotypes: A Mendelian randomization study. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e044720   | 1.2  |   |
| 92  | The effect of physical activity on CSF biomarkers of Alzheimer's disease differs between men and women. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e044722  | 1.2  |   |
| 91  | Multiple biological pathways associate with cerebral amyloid load in the early Alzheimer's continuum. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e044733  | 1.2  |   |
| 90  | Higher fronto-parietal metabolism parallels a greater impact of amyloid and anxiety on medial temporal areas in women versus men. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e044780  | 1.2  |   |
| 89  | Higher CSF STREMB2/P-tau ratio levels attenuate effects of polygenic Alzheimer's disease risk on cognitive decline and neurodegeneration. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e044800  | 1.2  |   |
| 88  | Air pollution and biomarkers of Alzheimer's disease in cognitively unimpaired individuals. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e044802   | 1.2  | 0 |

|    |   |      |    |
|----|---|------|----|
| 87 | Multiple pathophysiological biomarkers are associated with gray matter volume and cerebral glucose metabolism in the early preclinical Alzheimer's continuum. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e044808   | 1.2  |    |
| 86 | APOE- $\epsilon$ shapes temporo-parietal network properties in middle-aged, cognitively unimpaired individuals: A graph theory analysis. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e045092  | 1.2  |    |
| 85 | Weight loss predicts Alzheimer's disease biomarker positivity in cognitively unimpaired middle-aged adults. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e045137   | 1.2  |    |
| 84 | Proximity to parental age at onset exacerbates amyloid burden while mental conditions exacerbate neural loss during midlife. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e045171  | 1.2  |    |
| 83 | Incidence of subjective cognitive decline is associated with amyloid- $\beta$ pathology, whereas stability relates to neurodegeneration. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e045293  | 1.2  |    |
| 82 | Amyloid-positive individuals with subjective cognitive decline present increased CSF neurofilament light levels that relate to hippocampal volume. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e045715  | 1.2  |    |
| 81 | Impact of APOE- $\epsilon$ on cerebral amyloid deposition in participants with abnormal soluble amyloid levels. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e045828   | 1.2  | 1  |
| 80 | Cross-modal associations between traditional and emerging CSF biomarkers and grey matter network disruption in autosomal dominant Alzheimer disease. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e045905  | 1.2  | 1  |
| 79 | International initiative for harmonization of cerebrospinal fluid diagnostic comments in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e047209   | 1.2  | 1  |
| 78 | Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e047539  | 1.2  | 2  |
| 77 | Quantitative informant- and self-reports of subjective cognitive decline predict amyloid beta PET outcomes in cognitively unimpaired individuals independently of age and. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2020</b> , 12, e12127 | 5.2  | 3  |
| 76 | Eating a Weekly Serving of Walnuts Relates to Beneficial Brain Imaging Phenotypes in a Cohort at Increased Risk of Alzheimer's Disease. <i>Current Developments in Nutrition</i> , <b>2020</b> , 4, 1234-1234   | 0.4  | 0  |
| 75 | Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, 1358-1371   | 1.2  | 44 |
| 74 | Earliest amyloid and tau deposition modulate the influence of limbic networks during closed-loop hippocampal downregulation. <i>Brain</i> , <b>2020</b> , 143, 976-992  | 11.2 | 8  |
| 73 | An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. <i>Nature Reviews Neurology</i> , <b>2020</b> , 16, 265-284  | 15   | 53 |
| 72 | White matter microstructure and cerebrospinal fluid biomarkers of Alzheimer's disease in middle-aged cognitively unimpaired participants (the ALFA study). <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e043027  | 1.2  |    |
| 71 | Association between insomnia and cognitive performance, gray matter volume, and white matter microstructure in cognitively unimpaired adults. <i>Alzheimer's Research and Therapy</i> , <b>2020</b> , 12, 4   | 9    | 24 |
| 70 | White matter hyperintensities mediate gray matter volume and processing speed relationship in cognitively unimpaired participants. <i>Human Brain Mapping</i> , <b>2020</b> , 41, 1309-1322   | 5.9  | 13 |

|    |   |      |     |
|----|---|------|-----|
| 69 | Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration. <i>Molecular Neurodegeneration</i> , <b>2020</b> , 15, 57  | 19   | 16  |
| 68 | Sex Differences of Longitudinal Brain Changes in Cognitively Unimpaired Adults. <i>Journal of Alzheimer's Disease</i> , <b>2020</b> , 76, 1413-1422   | 4.3  | 1   |
| 67 | Association of years to parent's sporadic onset and risk factors with neural integrity and Alzheimer biomarkers. <i>Neurology</i> , <b>2020</b> , 95, e2065-e2074   | 6.5  | 1   |
| 66 | Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. <i>Acta Neuropathologica</i> , <b>2020</b> , 140, 267-278                    | 14.3 | 79  |
| 65 | Higher CSF sTREM2 and microglia activation are associated with slower rates of beta-amyloid accumulation. <i>EMBO Molecular Medicine</i> , <b>2020</b> , 12, e12308   | 12   | 34  |
| 64 | Effect of BDNF Val66Met on hippocampal subfields volumes and compensatory interaction with APOE- $\epsilon$ in middle-age cognitively unimpaired individuals from the ALFA study. <i>Brain Structure and Function</i> , <b>2020</b> , 225, 2331-2345  | 4    | 3   |
| 63 | Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's continuum when only subtle changes in A $\beta$ pathology are detected. <i>EMBO Molecular Medicine</i> , <b>2020</b> , 12, e12921 | 12   | 67  |
| 62 | Patterns of white matter hyperintensities associated with cognition in middle-aged cognitively healthy individuals. <i>Brain Imaging and Behavior</i> , <b>2020</b> , 14, 2012-2023   | 4.1  | 17  |
| 61 | Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer's disease. <i>Science Translational Medicine</i> , <b>2019</b> , 11,  | 17.5 | 103 |
| 60 | Interactive effect of age and APOE- $\epsilon$ allele load on white matter myelin content in cognitively normal middle-aged subjects. <i>NeuroImage: Clinical</i> , <b>2019</b> , 24, 101983  | 5.3  | 6   |
| 59 | Spatial patterns of white matter hyperintensities associated with Alzheimer's disease risk factors in a cognitively healthy middle-aged cohort. <i>Alzheimer's Research and Therapy</i> , <b>2019</b> , 11, 12  | 9    | 24  |
| 58 | Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimer's disease. <i>Scientific Reports</i> , <b>2019</b> , 9, 7803   | 4.9  | 16  |
| 57 | Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers. <i>Alzheimer's Research and Therapy</i> , <b>2019</b> , 11, 27   | 9    | 45  |
| 56 | Glial Activation Markers in CSF and Serum From Patients With Primary Progressive Multiple Sclerosis: Potential of Serum GFAP as Disease Severity Marker?. <i>Frontiers in Neurology</i> , <b>2019</b> , 10, 280                                       | 4.1  | 41  |
| 55 | CSF glial biomarkers YKL40 and sTREM2 are associated with longitudinal volume and diffusivity changes in cognitively unimpaired individuals. <i>NeuroImage: Clinical</i> , <b>2019</b> , 23, 101801   | 5.3  | 17  |
| 54 | The gene cluster is a key modulator of soluble TREM2 and Alzheimer's disease risk. <i>Science Translational Medicine</i> , <b>2019</b> , 11,  | 17.5 | 77  |
| 53 | CHARACTERIZATION OF COGNITIVE PERFORMANCE, GRAY MATTER VOLUME AND WHITE MATTER MICROSTRUCTURE IN COGNITIVELY UNIMPAIRED ADULTS WITH INSOMNIA SYMPTOMS <b>2019</b> , 15, P207-P209 <sup>o</sup>  |      |     |
| 52 | P4-573: PROXIMITY TO PARENTAL ONSET AND APOE $\epsilon$ INDEPENDENTLY CONTRIBUTE TO AMYLOID BURDEN IN MIDDLE-AGED ADULTS WITH A FAMILY HISTORY OF SPORADIC ALZHEIMER'S DISEASE <b>2019</b> , 15, P1539-P1539  |      |     |

|    |   |      |     |
|----|---|------|-----|
| 51 | O3-02-01: APOE- $\epsilon$ ALLELIC LOAD MODULATES THE ASSOCIATION BETWEEN CSF BETA-AMYLOID AND GRAY MATTER VOLUME IN COGNITIVELY UNIMPAIRED INDIVIDUALS <b>2019</b> , 15, P877-P878   |      |     |
| 50 | O3-11-01: INFORMANT RATINGS, BUT NOT SELF-REPORTS, OF COGNITIVE DECLINE PREDICT AMYLOID PET POSITIVITY IN COGNITIVELY UNIMPAIRED MIDDLE-AGED INDIVIDUALS <b>2019</b> , 15, P910-P911  |      |     |
| 49 | Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers. <i>Alzheimer's Research and Therapy</i> , <b>2019</b> , 11, 94   | 9    | 15  |
| 48 | Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer's disease. <i>Therapeutic Advances in Neurological Disorders</i> , <b>2019</b> , 12, 1756286419888819  | 6.6  | 24  |
| 47 | Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-neurodegeneration but not with amyloid- $\beta$ pathology. <i>Molecular Neurodegeneration</i> , <b>2019</b> , 14, 1  | 19   | 110 |
| 46 | Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimer's disease. <i>Brain</i> , <b>2018</b> , 141, 1186-1200   | 11.2 | 54  |
| 45 | Distinct Cognitive and Brain Morphological Features in Healthy Subjects Unaware of Informant-Reported Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , <b>2018</b> , 65, 181-191  | 4.3  | 11  |
| 44 | Brain and cognitive correlates of subjective cognitive decline-plus features in a population-based cohort. <i>Alzheimer's Research and Therapy</i> , <b>2018</b> , 10, 123  | 9    | 57  |
| 43 | P1-137: REDUCED ENTORHINAL GRAY MATTER VOLUME IN HEALTHY AMYLOID-NEGATIVE APOE-E4 HOMOZYGOTES OF THE ALFA COHORT <b>2018</b> , 14, P326-P327  |      |     |
| 42 | O3-12-02: SUBJECTS WITHOUT SELF-AWARENESS OF COGNITIVE DECLINE PRESENT DIFFERENT COGNITIVE AND BRAIN MORPHOLOGICAL FEATURES <b>2018</b> , 14, P1050-P1051   |      |     |
| 41 | CSF progranulin increases in the course of Alzheimer's disease and is associated with sTREM2, neurodegeneration and cognitive decline. <i>EMBO Molecular Medicine</i> , <b>2018</b> , 10,   | 12   | 41  |
| 40 | White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimer's disease. <i>Brain</i> , <b>2018</b> , 141, 3065-3080   | 11.2 | 72  |
| 39 | Episodic memory and executive functions in cognitively healthy individuals display distinct neuroanatomical correlates which are differentially modulated by aging. <i>Human Brain Mapping</i> , <b>2018</b> , 39, 4565-4579                                      | 5.9  | 22  |
| 38 | The $\epsilon$ genotype modulates CSF YKL-40 levels and their structural brain correlates in the continuum of Alzheimer's disease but not those of sTREM2. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2017</b> , 6, 50-59 | 5.2  | 29  |
| 37 | CSF sAPP $\beta$ YKL-40, and neurofilament light in frontotemporal lobar degeneration. <i>Neurology</i> , <b>2017</b> , 89, 178-188   | 6.5  | 75  |
| 36 | The FTD-like syndrome causing TREM2 T66M mutation impairs microglia function, brain perfusion, and glucose metabolism. <i>EMBO Journal</i> , <b>2017</b> , 36, 1837-1853  | 13   | 110 |
| 35 | [P2 $\beta$ 55]: CSF STREM2, BUT NOT YKL-40, IS ASSOCIATED WITH LONGITUDINAL MORPHOLOGICAL BRAIN CHANGES IN PRECLINICAL ALZHEIMER'S DISEASE <b>2017</b> , 13, P758-P758   |      |     |
| 34 | [O10206]: ELEVATED CSF STREM2 IN AUTOSOMAL DOMINANTLY INHERITED ALZHEIMER'S DISEASE ASSOCIATED WITH REGIONAL FIBER TRACT INJURY: RESULTS FROM THE DIAN STUDY <b>2017</b> , 13, P188-P189  |      |     |



|    |  |      |     |
|----|--|------|-----|
| 33 | Increase of TREM2 during Aging of an Alzheimer's Disease Mouse Model Is Paralleled by Microglial Activation and Amyloidosis. <i>Frontiers in Aging Neuroscience</i> , <b>2017</b> , 9, 8   | 5.3  | 47  |
| 32 | Cerebrospinal fluid sTREM2 levels are associated with gray matter volume increases and reduced diffusivity in early Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2016</b> , 12, 1259-1272                               | 1.2  | 67  |
| 31 | Monomethylated and unmethylated FUS exhibit increased binding to Transportin and distinguish FTLD-FUS from ALS-FUS. <i>Acta Neuropathologica</i> , <b>2016</b> , 131, 587-604  | 14.3 | 56  |
| 30 | sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers. <i>EMBO Molecular Medicine</i> , <b>2016</b> , 8, 466-476          | 12   | 256 |
| 29 | Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injury. <i>Science Translational Medicine</i> , <b>2016</b> , 8, 369ra178  | 17.5 | 155 |
| 28 | IC-P-115: CSF Levels of Strem2 are Associated With Greater Frontal Cortical Thickness During Advanced Disease Stages in Autosomal Dominant Alzheimer Disease <b>2016</b> , 12, P86-P87   |      |     |
| 27 | F5-02-04: CSF STREM2 Levels Increase in Early Stages of Autosomal Dominant Alzheimer's Disease (ADAD) and are Associated with Markers of Neuronal Injury <b>2016</b> , 12, P369-P370   |      |     |
| 26 | Early Cerebellar Hypometabolism in Patients With Frontotemporal Dementia Carrying the C9orf72 Expansion. <i>Alzheimer Disease and Associated Disorders</i> , <b>2015</b> , 29, 353-6   | 2.5  | 7   |
| 25 | Characterization of the repeat expansion size in C9orf72 in amyotrophic lateral sclerosis and frontotemporal dementia. <i>Human Molecular Genetics</i> , <b>2014</b> , 23, 749-54  | 5.6  | 84  |
| 24 | Autosomal-dominant Alzheimer's disease mutations at the same codon of amyloid precursor protein differentially alter A $\beta$ production. <i>Journal of Neurochemistry</i> , <b>2014</b> , 128, 330-9                               | 6    | 24  |
| 23 | Plasma phosphorylated TDP-43 levels are elevated in patients with frontotemporal dementia carrying a C9orf72 repeat expansion or a GRN mutation. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2014</b> , 85, 684-91 | 5.5  | 47  |
| 22 | Relationship between $\beta$ Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , <b>2014</b> , 42, 157-67   | 4.3  | 88  |
| 21 | TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. <i>Science Translational Medicine</i> , <b>2014</b> , 6, 243ra86   | 17.5 | 436 |
| 20 | Reversal of neurofibrillary tangles and tau-associated phenotype in the rTgTauEC model of early Alzheimer's disease. <i>Journal of Neuroscience</i> , <b>2013</b> , 33, 13300-11   | 6.6  | 35  |
| 19 | Endothelial progenitor cells in acute ischemic stroke. <i>Brain and Behavior</i> , <b>2013</b> , 3, 649-55   | 3.4  | 32  |
| 18 | Distinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer disease. <i>Acta Neuropathologica</i> , <b>2013</b> , 125, 201-13  | 14.3 | 81  |
| 17 | Prazosin, an $\alpha$ 1-adrenoceptor antagonist, prevents memory deterioration in the APP23 transgenic mouse model of Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2013</b> , 34, 1105-15                                  | 5.6  | 34  |
| 16 | Comparison of 2 diagnostic criteria for the behavioral variant of frontotemporal dementia. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , <b>2013</b> , 28, 469-76   | 2.5  | 10  |

|    |  |      |     |
|----|--|------|-----|
| 15 | Statin pretreatment may increase the risk of symptomatic intracranial haemorrhage in thrombolysis for ischemic stroke: results from a case-control study and a meta-analysis. <i>Journal of Neurology</i> , <b>2012</b> , 259, 111-8 | 5.5  | 38  |
| 14 | Expansion mutation in C9ORF72 does not influence plasma progranulin levels in frontotemporal dementia. <i>Neurobiology of Aging</i> , <b>2012</b> , 33, 1851.e17-9   | 5.6  | 12  |
| 13 | Propagation of tau pathology in a model of early Alzheimer's disease. <i>Neuron</i> , <b>2012</b> , 73, 685-97   | 13.9 | 969 |
| 12 | Propagation of Tau Pathology in a Model of Early Alzheimer's Disease. <i>Neuron</i> , <b>2012</b> , 76, 461  | 13.9 | 3   |
| 11 | Tau enhances $\beta$ -synuclein aggregation and toxicity in cellular models of synucleinopathy. <i>PLoS ONE</i> , <b>2011</b> , 6, e26609  | 3.7  | 94  |
| 10 | Dementia risk in Parkinson disease: disentangling the role of MAPT haplotypes. <i>Archives of Neurology</i> , <b>2011</b> , 68, 359-64   |      | 102 |
| 9  | Pachymeningitis, Painful Ophthalmoplegia, and Multiple Cranial Neuropathy of Presumed Tuberculous Origin. <i>Neuro-Ophthalmology</i> , <b>2011</b> , 35, 289-292   | 0.9  | 1   |
| 8  | PL-05-01: A transgenic model of the earliest stage of Alzheimer's disease <b>2010</b> , 6, S165-S165   |      |     |
| 7  | Polyradiculoneuropathy associated to human herpesvirus 2 in an HIV-1-infected patient (Elsberg syndrome): case report and literature review. <i>Sexually Transmitted Diseases</i> , <b>2010</b> , 37, 123-5                          | 2.4  | 11  |
| 6  | Tau phosphorylation and aggregation as a therapeutic target in tauopathies. <i>CNS and Neurological Disorders - Drug Targets</i> , <b>2010</b> , 9, 727-40   | 2.6  | 18  |
| 5  | Blood pressure is not associated with haematoma enlargement in acute intracerebral haemorrhage. <i>European Journal of Neurology</i> , <b>2008</b> , 15, 1085-90   | 6    | 15  |
| 4  | ZIC antibodies in paraneoplastic cerebellar degeneration and small cell lung cancer. <i>Journal of Neuroimmunology</i> , <b>2008</b> , 201-202, 163-5  | 3.5  | 33  |
| 3  | Time course of phosphorylated tau181 in blood across the Alzheimer's disease spectrum  |      | 2   |
| 2  | Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative  |      | 1   |
| 1  | The MS4A gene cluster is a key regulator of soluble TREM2 and Alzheimer disease risk   |      | 4   |